Eculizumab (Soliris®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015000972
English
Authors' recommendations:
The National Institute for Health and Care Excellence (NICE) published advice in January 2015 in relation to eculizumab (Soliris®) for the treatment of patients with atypical haemolytic uraemic syndrome (aHUS). At their meeting on 11th February 2015 AWMSG supported the adoption and implementation of this advice within NHS Wales (refer to the minutes of meetings). The Minister for Health and Social Services has subsequently agreed that the NICE HST advice for eculizumab (Soliris®) should be implemented within NHS Wales. A National Clinical Access Policy will be developed by Welsh Health Specialised Services Committee (WHSSC) with the support of clinical experts, patient representatives and other key stakeholders. Refer to the NICE website for full guidance including any specific restrictions on the use of the technology.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1153
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Antibodies, Monoclonal, Humanized
- Complement Inactivating Agents
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.